Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值

doi:10.3969/j.issn.1673-8640.2017.04.017

检验医学 ›› 2017, Vol. 32 ›› Issue (4): 322-325.DOI: 10.3969/j.issn.1673-8640.2017.04.017

Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值

赵培玉, 陈敖峥, 秦锦龙, 宋力雯, 成佳景

同济大学附属上海市第十人民医院,上海 200072

收稿日期:2016-12-28 出版日期:2017-04-20 发布日期:2017-05-01
作者简介:null
作者简介：赵培玉,女,1992年生,硕士,主要从事人乳头瘤病毒感染研究。陈敖峥,男,1986年生,硕士,主治医师,主要从事妇科肿瘤研究。赵培玉和陈敖峥对本研究具有同等贡献,并列为第一作者。
基金资助:
上海市科学技术委员会资助项目（15695841100）

Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening

ZHAO Peiyu, CHEN Aozheng, QIN Jinlong, SONG Liwen, CHENG Jiajing

Shanghai Tenth People's Hospital,Tongji University,Shanghai 200072,China

Received:2016-12-28 Online:2017-04-20 Published:2017-05-01

摘要/Abstract

摘要：

目的评价Cervista高危型人乳头瘤病毒（HR-HPV）DNA检测联合薄层液基细胞学检查（TCT）在宫颈癌筛查中的临床价值。方法收集阴道镜活检病理结果为癌前病变及宫颈癌的患者745例,行TCT及Cervista HR-HPV DNA检测,以病理学诊断为金标准,比较TCT、Cervista HR-HPV DNA检测及Cervista HR-HPV DNA检测联合TCT的结果,评价Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值。结果 TCT的特异性最高,为50.40%,而Cervista HR-HPV DNA检测联合TCT的敏感性和阴性预测值均最高,分别为92.51%、82.31%。结论 Cervista HR-HPV DNA检测对于宫颈癌的检出率较TCT高,而二者联合筛查可显著提高敏感性和阴性预测值,降低漏诊率。

关键词: 高危型人乳头瘤病毒, DNA, 薄层液基细胞学, 宫颈癌

Abstract:

Objective To evaluate Cervista high-risk human papillomavirus （HR-HPV）DNA testing combined with thin cytology test （TCT）in cervical cancer screening. Methods A total of 745 female patients were diagnosed as precancerous lesions or cervical cancer with pathological diagnosis as gold standard. The performance of TCT,Cervista HR-HPV DNA testing and Cervista HR-HPV DNA testing combined with TCT were evaluated. The role of Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening was evaluated. Results The specificity of TCT was the best（50.40%）. The sensitivity and negative predictive value of Cervista HR-HPV DNA testing combined with TCT were 92.51% and 82.31%,which were higher than those of single determinations. Conclusions The determination rate of Cervista HR-HPV DNA testing is higher than that of TCT,the combined determination can improve the sensitivity and negative predictive valve effectively,and can decrease the rate of missed diagnosis and false positive rate.

Key words: High-risk human papillomavirus, DNA, Thin cytology test, Cervical cancer

中图分类号:

R446.5

赵培玉, 陈敖峥, 秦锦龙, 宋力雯, 成佳景. Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值[J]. 检验医学, 2017, 32(4): 322-325.

ZHAO Peiyu, CHEN Aozheng, QIN Jinlong, SONG Liwen, CHENG Jiajing. Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening[J]. Laboratory Medicine, 2017, 32(4): 322-325.

图/表 4

参考文献 13

[1]	WANG B,HE M,CHAO A,et al.Cervical cancer screening among adult women in China,2010[J]. Oncologist,2015,20(6):627-634.
[2]	DE SANJOSE S,QUINT W G,ALEMANY L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J]. Lancet Oncol,2010,11(11):1048-1056.
[3]	SCHWARZ E,FREESE U K,GISSMANN L,et al.Structure and transcription of human papil-lomavirus sequences in cervical carcinoma cells[J]. Nature,1985,314(6006):111-114.
[4]	RICHARDSON H,KELSALL G,TELLIER P,et al.The natural history of type-specific human papillomavirus infections in female university students[J]. Cancer Epidemiol Biomarkers Prev,2003,12(6):485-490.
[5]	CAI T,PERLETTI G,MEACCI F,et al.Natural history of human papillomavirus infection in non-vaccinated young males: low clearance probability in high-risk genotypes[J]. Eur J Clin Microbiol Infect Dis,2016,35(3):463-469.
[6]	DE SANJOSE S,QUINT W G,ALEMANY L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J]. Lancet Oncol,2010,11(11):1048-1056.
[7]	SASLOW D,SOLOMON D,LAWSON H W,et al.American Cancer Society,American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer[J]. Am J Clin Pathol,2012,137(4):516-542.
[8]	WU E Q,LIU B,CUI J F,et al.Prevalence of type-specific human papillomavirus and pap results in Chinese women:a multi-center,population-based cross-sectional study[J]. Cancer Causes Control,2013,24(4):795-803.
[9]	LI C,WU M,WANG J,et al.A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing,People's Republic of China[J]. Cancer Epi-demiol Biomarkers Prev,2010,19(10):2655-2664.
[10]	KIM S,ARDUINO J M,ROBERTS C C,et al.Incidence and predictors of human papillomavirus-6,-11,-16,and -18 infection in young norwegian women[J]. Sex Transm Dis,2011,38(7):587-597.
[11]	KIM H S,KIM T J,LEE I H,et al.Associations between sexually transmitted infections,high-risk human papillomavirus infection,and abnormal cervical Pap smear results in OB/GYN outpa-tients[J]. J Gynecol Oncol,2016,27(5):e49.
[12]	YOUENS K E,HOSLER G A,WASHINGTON P J,et al.Clinical experience with the Cervista HPV HR assay:correlation of cytology and HPV status from 56,501 specimens[J]. J Mol Diagn,2011,13(2):160-166.
[13]	ROZEMEIJER K,PENNING C,SIEBERS A G,et al.Comparing SurePath,ThinPrep,and conventional cytology as primary test method:SurePath is associated with increased CIN Ⅱ+ detection rates[J]. Cancer Causes Control,2016,27(1):15-25.

TCT	病理诊断		合计
TCT	阳性	阴性	合计
阳性	273	184	457
阴性	101	187	288
合计	374	371	745

TCT	病理诊断		合计
TCT	阳性	阴性	合计
阳性	273	184	457
阴性	101	187	288
合计	374	371	745

Cervista HR-HPV DNA检测	病理诊断		合计
Cervista HR-HPV DNA检测	阳性	阴性	合计
阳性	314	252	566
阴性	60	119	179
合计	374	371	745

Cervista HR-HPV DNA检测	病理诊断		合计
Cervista HR-HPV DNA检测	阳性	阴性	合计
阳性	314	252	566
阴性	60	119	179
合计	374	371	745

联合检测	病理诊断		合计
联合检测	阳性	阴性	合计
阳性	348	250	598
阴性	26	121	147
合计	374	371	745

Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值

Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 13

相关文章 15

编辑推荐

Metrics

方法	敏感性（%）	特异性（%）	阴性预测值（%）	阳性预测值（%）
TCT	72.99	50.40	64.93	59.74
Cervista HR-HPV DNA检测	83.96	32.08	66.48	44.52
Cervista HR-HPV DNA检测联合TCT	92.51	32.61	82.31	58.19

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	王慧英, 汤昱, 董利利, 王静. 肺炎支原体RNA检测用于肺炎患儿疾病诊断和疗效监测[J]. 检验医学, 2023, 38(9): 865-869.
[3]	梁栋, 梅月, 王腾蛟, 喻东. 基于cfDNA的NGS技术探究术后脓毒症患者血液微生物群特征[J]. 检验医学, 2023, 38(8): 753-759.
[4]	潘信, 吕颖, 李阳, 李荣国. miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性[J]. 检验医学, 2023, 38(7): 640-646.
[5]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[6]	吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195.
[7]	陈馨宁, 黄斐, 姜惠琴, 沈敏娜, 潘柏申, 王蓓丽, 郭玮. 非小细胞肺癌患者血浆EGFR基因c.2572_2573delinsAG位点突变1例报道[J]. 检验医学, 2023, 38(10): 1003-1005.
[8]	张亚旭, 崔延伟, 刘紫烟. 核酸分子杂交-流式细胞术检测HPV E6/E7 mRNA初步研究[J]. 检验医学, 2023, 38(1): 46-50.
[9]	王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状[J]. 检验医学, 2022, 37(9): 877-881.
[10]	王筱雨, 色米热·艾尼瓦尔, 李士军. 样本状态对血浆EB病毒DNA检测结果准确性的影响[J]. 检验医学, 2022, 37(7): 615-617.
[11]	朱赟洁, 马峥尧, 沈敏娜, 周琰, 黄斐, 陈馨宁, 张春燕, 王蓓丽, 郭玮. 结直肠癌患者血浆cfDNA检测方法的建立及临床应用评估[J]. 检验医学, 2022, 37(6): 561-567.
[12]	张小勤, 周玉兰, 付竹梅, 韩学学, 展洁. 线粒体DNA T16189C变异与妊娠糖尿病的关系[J]. 检验医学, 2022, 37(5): 413-416.
[13]	马艳婷, 苏曦, 黄斐, 王梦娴, 沈敏娜, 张春燕, 王蓓丽, 潘柏申, 郭玮. HBV RNA检测在慢性乙型肝炎中的临床价值[J]. 检验医学, 2022, 37(1): 72-77.
[14]	胥明勇, 朱华强, 吴泳桦, 庄利东. 沙眼衣原体DNA质控物的制备及评价[J]. 检验医学, 2021, 36(1): 107-110.
[15]	房永贇, 卢大儒, 沈立松. 循环KRAS突变检测在结直肠癌患者新辅助治疗疗效中的临床价值探讨[J]. 检验医学, 2020, 35(9): 875-880.